Emergency and Critical Care Medicine 2024年第4期创伤专题正式上线, 本期由1篇Perspective/Viewpoint,3篇Original article,2篇Review,1篇Communication ...
ELLISSA Baskind thought her back pain was due to the long hours she spent as a gynaecologist bending over during operations.
Vactosertib is under clinical development by MedPacto and currently in Phase I for Relapsed Acute Myeloid Leukemia.
Venetoclax is under clinical development by AbbVie and currently in Phase II for Refractory Acute Myeloid Leukemia.
Fatigue is a key prognostic indicator for adverse outcomes in AML, ALL, and myelodysplastic syndromes. CAR T-cell therapy post-transplant shows a 48% complete remission rate in AML, though not FDA ...
Jan. 17, 2020 — A common and inexpensive drug may be used to counteract treatment resistance in patients with acute myeloid leukemia (AML), one of the most common forms of blood cancer. The ...
A workaholic doctor thought her extreme back pain was just stress-related when she was diagnosed with acute myeloid leukaemia ...
Moleculin Biotech ( (MBRX) ) has provided an update.
A shorter duration of venetoclax treatment for newly diagnosed acute myeloid leukemia (AML) may enhance efficacy and reduce toxicity, according to Amir Ali, PharmD, BCOP. Tailoring the duration of ...